Varenicline (Chantix) for tobacco dependence

Medical Letter on Drugs and Therapeutics

Volumn 48, Issue 1241-1242, 2006, Pages 66-68

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CIMETIDINE; COMMIT; DOPAMINE; NICOTINE; NICOTINE GUM; PLACEBO; VARENICLINE; ALPHA(4)BETA(4) NICOTINIC RECEPTOR; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; NICOTINIC RECEPTOR; QUINOXALINE DERIVATIVE;

ABNORMAL DREAMING; ANOREXIA; ANXIETY; BURNING SENSATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COUGHING; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FIBROMA; FLATULENCE; HEADACHE; HEARTBURN; HICCUP; HUMAN; HYPERSENSITIVITY REACTION; INDIGESTION; INSOMNIA; JAW DISEASE; LACRIMATION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUTH DISEASE; MOUTH IRRITATION; MOUTH PAIN; NASAL MUCOSA BURNING; NAUSEA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SHORT SURVEY; SIDE EFFECT; SMOKING CESSATION; SNEEZING; SORE JAW; SORE THROAT; STEVENS JOHNSON SYNDROME; TASTE DISORDER; THROAT IRRITATION; TOBACCO DEPENDENCE; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; DRUG INTERACTION; METABOLISM;

BENZAZEPINES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; NAUSEA; NICOTINIC AGONISTS; QUINOXALINES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, NICOTINIC; SMOKING CESSATION; TOBACCO USE DISORDER; WEIGHT GAIN;

EID: 33749316780     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (11)

1. Drugs for tobacco dependence. Treat Guidel Med Lett 2003; 1:65.
2. JW Coe et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48:3474.
3. RS Obach et al. Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 2006; 34:121.
4. D Gonzales et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296:47.
5. DE Jorenby et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustainedrelease bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296:56.
6. S Tonstad et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296:64.
7. RD Hurt et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337:1195.
8. DE Jorenby et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340:685.
9. JT Hays et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Intern Med 2001; 135:423.
10. DP Sachs et al. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med 1993; 153:1881.
11. J Gross et al. Nicotine replacement: effects of postcessation weight gain. J Consult Clin Psychol 1989; 57:87.